Show simple item record

dc.contributor.authorGupta, A
dc.contributor.authorAnjomani-Virmouni, S
dc.contributor.authorKoundouros, N
dc.contributor.authorPoulogiannis, G
dc.date.accessioned2018-01-24T15:39:46Z
dc.date.issued2017-01
dc.identifier.citationMolecular & cellular oncology, 2017, 4 (6), pp. e1329692 - ?
dc.identifier.issn2372-3556
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1025
dc.identifier.eissn2372-3556
dc.identifier.doi10.1080/23723556.2017.1329692
dc.description.abstractCancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation.
dc.formatElectronic-eCollection
dc.format.extente1329692 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.
dc.typeJournal Article
dcterms.dateAccepted2017-05-09
rioxxterms.versionofrecord10.1080/23723556.2017.1329692
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfMolecular & cellular oncology
pubs.issue6
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism
pubs.publication-statusPublished
pubs.volume4
pubs.embargo.termsNo embargo
icr.researchteamSignalling & Cancer Metabolismen_US
dc.contributor.icrauthorPoulogiannis, Georgiosen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0